<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hamata, Amor</style></author><author><style face="normal" font="default" size="100%">Aissi, Salim</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Exploring Equilibrium Points in a Long-term Glucose-insulin Model for Type I Diabetes: MPC Application in Automated Insulin Delivery Systems Using Functional Insulin Therapy Tools</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal Bioautomation</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2025</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.biomed.bas.bg/bioautomation/2025/vol_29.1/files/29.1_04.pdf</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">29</style></volume><pages><style face="normal" font="default" size="100%">51-76 </style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p style=&quot;text-align: justify;&quot;&gt;
	This study explores a novel approach to regulate blood glucose levels in individuals with type I diabetes, employing the widely used model predictive control (MPC) strategy in type 1 diabetes mellitus therapy and clinical trials. The MPC algorithm is implemented based on Magdelaine’s long-term glucose-insulin model, which encompasses real-life characteristics often absent in other prevalent models. The control strategy is evaluated through simulations involving 10 virtual patients from existing literature. The simulations encompass fasting scenarios and a closed-loop control scenario involving three meals. MPC results are compared to those of the “optimal” conventional insulin daily injections therapy (open-loop treatment), especially under “aggressive conditions” including elevated initial blood glucose levels, substantial carbohydrate intake, closely spaced meal times, and incorporating a time delay between plasma glucose concentration and its subcutaneous measurement. The MPC algorithm demonstrated remarkable efficacy in glycemic control for 80% of patients, achieving an average time-in-range percentage exceeding 80% with no hypoglycemic episodes. This aligns with the American Diabetes Association’s recommendation of spending at least 70% of the time in the target range for effective glycemic control and maintaining an average time spent in hypoglycemia of less than 4%. However, the same MPC controller exhibited suboptimal performance for two patients, with an average time spent in hypoglycemia exceeding 8%. These findings underscore the need for individualized adjustments of MPC parameters or alternative control strategies to optimize glycemic management in all patients.
&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue></record></records></xml>